@misc{10481/67333,
year = {2021},
month = {2},
url = {http://hdl.handle.net/10481/67333},
abstract = {Goals of endocrine therapy for advanced breast cancer (ABC) include prolonging survival rates,
maintaining the quality of life, and delaying the initiation of chemotherapy. We evaluated the
effectiveness of fulvestrant as first-line in patients with estrogen receptor (ER)-positive ABC with
relapse during or after adjuvant anti-estrogenic therapy in real-world settings. Retrospective,
observational study involving 171 postmenopausal women with ER-positive ABC who received
fulvestrant as first-line between January 2011 and May 2018 in Spanish hospitals. With a median
follow-up of 31.4 months, the progression-free survival (PFS) with fulvestrant was 14.6 months. No
differences were seen in the visceral metastatic (14.3 months) versus non-visceral (14.6 months)
metastatic subgroup for PFS. Overall response rate and clinical benefit rate were 35.2% and 82.8%.
Overall survival was 43.1 months. The duration of the clinical benefit was 19.2 months. Patients with
ECOG performance status 0 at the start of treatment showed a significant greater clinical benefit
rate and overall survival than with ECOG 1–2. Results in real-world settings are in concordance
with randomized clinical trials. Fulvestrant continues to demonstrate clinical benefits in real-world
settings and appears be well tolerated as first-line for the treatment of postmenopausal women with
ER-positive ABC.},
organization = {Astra Zeneca Spain S.A., Madrid, Spain},
publisher = {Nature Research},
title = {Real‑world data of fulvestrant as first‑line treatment of postmenopausal women with estrogen receptor‑positive metastatic breast cancer},
doi = {10.1038/s41598-021-83622-1},
author = {Blancas López-Barajas, María Isabel and Conde, V.},
}